{'fraction_non_alphanumeric': 0.02092050209205021, 'fraction_numerical': 0.055230125523012555, 'mean_word_length': 5.040404040404041, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[What are the trends in cardiovascular pharmacotherapy in recent years in patients after myocardial infarct?].

The authors compared the status of pharmacotherapy in 587 patients with myocardial infarction in 1991 according to the MONICA study, in hospitals of six districts in the Czech Republic, age group 25-64 years with data for 1995 assembled by means of questionnaires in 749 patients of the same age group, who were after myocardial infarction in selected spas. Thrombolytic treatment proved quite inadequate in 1988-1993 in six districts of the Czech Republic, although it rose slightly from mere 2.9% in 1988 to 11.1% in 1993. In 1995 25.4% patients with acute myocardial infarction were treated by thrombolytic treatment. Conversely anti-platelet treatment was very satisfactory in 1991 as well as in 1995. Promising was also the increase in treatment with beta-blockers and ACE inhibitors in 1995 as compared with 1991. Also the percentage of patients treated by hypolipidaemic treatment increased in 1995. This work indicates the favourable trends in pharmacotherapy of patients with acute myocardial infarction in the acute stage as well as in patients after myocardial infarction.